Clinical Trial Search

Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Number of Patients With Ani-tumor Activity After Taking OSI-774. — 7 participants

Primary: Dose-limiting Toxicity (DLT) (Phase I) — 1; 1 participants

Primary: Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) — 5 Participants

Primary: Number of Patients With Adverse Events (AEs) — 3; 8; 3 Participants

Primary: Progression-free Survival at 3 Months — 2.9 months

Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Progression Free Survival — 9.6 months

Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199

Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants

Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions

Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants

Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria — 14; 7; 4 Participants

Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants

Primary: Number of Participants According to Co-Diagnoses Before Index — 139; 45; 41; 26 Participants

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Response to Sunitinib Therapy — 13 participants

Primary: Progression-free Survival — 12 Weeks

Primary: Objective Response in ISM Good Risk Group — .23 proportion of participants — p=0.042

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Best Overall Response Rate — 33 percentage of participants

Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy

Primary: Objective Response Rate Assessed by RECIST Criteria. — 0; 3; 5; 9 participants

Primary: Observed Response Rate — 0; 11 percentage of patients responding

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: 3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope — 7.60 AU/second

Primary: Incidence of Durable Stable Disease, Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 18 particip[ants

Primary: Progression-free Survival (PFS) — 2.5 months